The Effect of Rosuvastatin on Adenosine Metabolism

Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00554138

Enrollment

Registered

2007-11-06

Start date

2007-11-30

Completion date

2008-04-30

Last updated

2008-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenosine Metabolism

Keywords

rosuvastatin, dipyridamole, caffeine

Brief summary

The aim of this study is to show whether rosuvastatin influences adenosine metabolism. Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increased adenosine receptor stimulation.

Interventions

DRUGplacebo

1 dd for 7-10 days

DRUGrosuvastatin

1 dd 20 mg for 7-10 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* age 18 - 50 years * Signed informed consent

Exclusion criteria

* hypertension * hypercholesterolemia * diabetes Mellitus * alanine aminotransferase \> 90 U/L * creatinine Kinase \> 440 U/L * cardiovascular disease * GFR \< 80 ml/min

Design outcomes

Primary

Measure	Time frame
forearm vasodilatory response to dipyridamole	7 days

Secondary

Measure	Time frame
lipid profile	7-10 days

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026